This week saw the FDA launch Elsa for internal drug review, MIT and Recursion release an open-source model for both protein structure and affinity prediction, and FutureHouse report AI-driven discovery of a dry AMD candidate. Insilico Medicine shared Phase IIa results for an AI-designed fibrosis drug in Nature Medicine, while ImmunoPrecise mapped a pan-…
Weekly Tech+Bio Highlights #43: New Foundation Model from MIT & Recursion
Also: Spatial Biology Means Terabyte-Scale Files, A Visual Guide to Genome Editors, Biotech VC Enters Quieter Phase, & Why AI Hallucinations May Be a Topological Problem
